Vanguard Group Inc. Sells 22,877 Shares of Artivion, Inc. $AORT

Key Points

• The Vanguard Group Inc. reduced its holdings in Artivion, Inc. by 0.8%, owning 2,782,007 shares valued at approximately $68.38 million after selling 22,877 shares.
• Insider sales included SVP Jean F. Holloway and insider John E. Davis, who sold 10,000 and 10,802 shares respectively, indicating a decrease in their ownership by 5.49% and 4.92%.
• Artivion has received mixed analyst ratings, with a consensus rating of "Buy" and an average target price of $40.63, following upgrades and downgrades by various analysts.

Vanguard Group Inc. decreased its stake in Artivion, Inc. (NYSE:AORT - Free Report) by 0.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,782,007 shares of the company's stock after selling 22,877 shares during the period. Vanguard Group Inc. owned 6.52% of Artivion worth $68,382,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of AORT. Legacy Advisors LLC acquired a new position in shares of Artivion during the 1st quarter worth approximately $28,000. MCF Advisors LLC grew its stake in shares of Artivion by 109.3% in the first quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock valued at $29,000 after buying an additional 614 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Artivion in the fourth quarter valued at $64,000. Raymond James Financial Inc. acquired a new position in Artivion during the fourth quarter worth $275,000. Finally, ProShare Advisors LLC raised its position in Artivion by 44.7% during the fourth quarter. ProShare Advisors LLC now owns 11,924 shares of the company's stock worth $341,000 after acquiring an additional 3,683 shares in the last quarter. Institutional investors own 86.37% of the company's stock.

Insider Transactions at Artivion

In related news, CEO James P. Mackin sold 12,500 shares of the business's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $42.32, for a total value of $529,000.00. Following the completion of the sale, the chief executive officer directly owned 852,783 shares in the company, valued at $36,089,776.56. The trade was a 1.44% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Marshall S. Stanton sold 18,200 shares of the business's stock in a transaction on Wednesday, August 27th. The shares were sold at an average price of $44.02, for a total value of $801,164.00. Following the completion of the sale, the senior vice president owned 64,200 shares of the company's stock, valued at $2,826,084. This trade represents a 22.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 115,990 shares of company stock valued at $4,435,823. Company insiders own 7.60% of the company's stock.

Artivion Stock Performance

AORT traded up $0.06 during trading hours on Friday, reaching $43.87. The company's stock had a trading volume of 342,981 shares, compared to its average volume of 627,565. Artivion, Inc. has a 52 week low of $21.97 and a 52 week high of $45.07. The company's 50-day moving average is $35.07 and its 200-day moving average is $29.32. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.48 and a current ratio of 4.78. The firm has a market cap of $2.07 billion, a PE ratio of -104.45 and a beta of 1.64.

Artivion (NYSE:AORT - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.13. The business had revenue of $112.97 million during the quarter, compared to the consensus estimate of $107.96 million. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The firm's revenue for the quarter was up 15.3% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Artivion, Inc. will post 0.37 EPS for the current year.

Analysts Set New Price Targets

AORT has been the subject of a number of analyst reports. Stifel Nicolaus lifted their price objective on shares of Artivion from $36.00 to $40.00 and gave the company a "buy" rating in a research report on Friday, August 8th. Wall Street Zen upgraded Artivion from a "hold" rating to a "buy" rating in a report on Monday. Canaccord Genuity Group boosted their price target on Artivion from $35.00 to $41.00 and gave the stock a "buy" rating in a research report on Friday, August 8th. Citizens Jmp upgraded Artivion to a "strong-buy" rating in a research note on Tuesday, May 6th. Finally, LADENBURG THALM/SH SH downgraded Artivion from a "buy" rating to a "neutral" rating and lifted their target price for the stock from $32.00 to $38.80 in a research note on Wednesday, August 13th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $40.63.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.